

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Pancreatic cancer	Glycogen synthase kinase 3 β (GSK3B)	<p>A study in cell culture identified maleimide-based GSK3B inhibitors that may help treat pancreatic cancer. GSK3B is overexpressed in some human colon and pancreatic carcinomas. In a panel of three pancreatic cancer cell lines, five of the GSK3B inhibitors decreased cell proliferation with IC₅₀ values in the nanomolar to low micromolar range. Next steps include evaluating the ADMET profiles of the inhibitors.</p> <p>Neu-120, a brain-permeable antioxidant targeting GSK3B and monoamine oxidase B (MAO-B) from Neurim Pharmaceuticals Ltd., is in Phase II testing to treat Parkinson's disease (PD).</p> <p>NP 12, a GSK3 inhibitor from Noscira S.A., is in Phase II testing for the same indication.</p> <p>SciBX 2(13); doi:10.1038/scibx.2009.530 Published online April 2, 2009</p>	Compounds patented for use in neurodegenerative disorders; available for licensing from the University of Illinois at Chicago Office of Technology Management	<p>Gaisina, I.N. <i>et al. J. Med. Chem.</i>; published online March 16, 2009; doi:10.1021/jm801317h</p> <p>Contact: Alan P. Kozikowski, University of Illinois at Chicago, Chicago, Ill. e-mail: kozikowa@uic.edu</p> <p>Contact: Daniel D. Billadeau, Mayo Clinic, Rochester, Minn. e-mail: Billadeau.Daniel@mayo.edu</p>